Cowen Maintains Buy on Regeneron Pharmaceuticals, Inc. (REGN) March 2026

On March 9, 2026, Cowen & Co. maintained a Buy on Regeneron Pharmaceuticals, Inc. (REGN), a clear signal in the latest REGN analyst rating update. Cowen said replicated U.S. results could lead to preferential prescribing for Regeneron’s therapy, keeping confidence high. The note came as REGN moved 2.29%, equal to $17.49 since the call. Meyka AI rates REGN with a grade of A based on S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.